Comparing Catalase Gene Therapy and MonoHER for Heart Protection
Author Information
Author(s): Abou El Hassan M A I, Rabelink M J W E, van der Vijgh W J F, Bast A, Hoeben R C
Primary Institution: Free University Medical Center, Leiden University Medical Center, University of Maastricht
Hypothesis
Can catalase gene therapy provide better protection against doxorubicin-induced cardiotoxicity compared to the cardioprotector monoHER?
Conclusion
The study found that a 3.5-fold increase in catalase was insufficient to protect against doxorubicin-induced cardiotoxicity, while monoHER provided significant protection.
Supporting Evidence
- A significant concentration-dependent reduction in the percentage of surviving NeRCaMs was observed within 48 hours after treatment with doxorubicin.
- 1 mM monoHER significantly protected against the lethal effect of doxorubicin on the survival of NeRCaMs during 48 hours after treatment.
- Doxorubicin significantly decreased the beating rate of NeRCaMs in a concentration- and time-dependent manner.
Takeaway
This study looked at how two treatments could help protect heart cells from damage caused by a cancer drug. One treatment worked well, while the other didn't help much.
Methodology
The study involved infecting neonatal rat cardiac myocytes with adenoviral vectors carrying the catalase gene and treating them with doxorubicin, followed by measuring cell survival, LDH release, and beating rate.
Limitations
The study was limited by the cytotoxic effects of high MOI of AdCat, which restricted the increase in catalase activity.
Participant Demographics
Neonatal Sprague-Dawley rats, 2-3 days old.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website